DelMar Pharma achieves halfway enrollment point for phase 2 clinical trial of VAL-083
DelMar Pharma announced its Phase 2 study testing VAL-083 in patients with newly diagnosed glioblastoma multiforme has achieved its halfway enrollment point. This trial is a single-arm, open-label study testing VAL-083 in combination with standard radiotherapy. February 20, 2019